Fluticasone furoate

Drug Profile

Fluticasone furoate

Alternative Names: 685698; Allermist; Aramisuto; Arnuity Ellipta; Avamys; GW-685698; GW-685698X; Veramyst

Latest Information Update: 26 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class Androstadienes; Antiallergics; Antiasthmatics; Glucocorticoids; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Asthma; Perennial allergic rhinitis; Seasonal allergic rhinitis
  • No development reported Rhinosinusitis

Most Recent Events

  • 18 Sep 2017 GlaxoSmithKline re-initiates enrolment in a phase II trial in Asthma (Treatment-experienced) in United Kingdom (Inhalation) (NCT02991859)
  • 29 Aug 2017 GlaxoSmithKline suspends patient enrolment in a phase II trial because of pending investigation of a manufacturing issue with the AMP challenge agent in Asthma (Treatment-experienced) in United Kingdom (Inhalation) (NCT02991859)
  • 24 Jul 2017 Preregistration for Asthma (In children, Prevention) in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top